Establishing a reference range for bone turnover markers in young, healthy women

被引:114
作者
Glover, S. J. [1 ]
Gamero, P. [2 ,3 ]
Naylor, K. [1 ]
Rogers, A. [1 ]
Eastell, R. [1 ]
机构
[1] Univ Sheffield, Sch Med, Sch Med & Biomed Sci, Acad Unit Bone Metab, Sheffield S10 2RX, S Yorkshire, England
[2] INSERM, Res Unit 664, F-69008 Lyon, France
[3] Synarc, Biochem Markers Div, Lyon, France
关键词
reference range; bone turnover markers; pre-menopausal; postmenopausal osteoporosis; antiresorptive therapy;
D O I
10.1016/j.bone.2007.12.218
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Biochemical markers of bone turnover (BTMs) are important in determining fracture risk in postmenopausal women; high levels being associated with increased risk. A proposed goal of anti-resorptive therapy is to reduce BTMs to the lower half of the reference range for healthy young pre-menopausal women. Our aims were a) to establish reference ranges for bone alkaline phosphatase (bone ALP), crosslinked C- and N-telopeptides of type 1 collagen (beta CTX, NTX), osteocalcin (OC) and procollagen type I N propeptide (PINP) in pre-menopausal women and b) to investigate the determinants of these BTMs. Methods: BTMs were measured in peripheral blood and second morning void urine collected from 200 healthy pre-menopausal women ages 30 to 45 years. Each subject completed a short medical and lifestyle questionnaire. Results: BTMs were higher before the age of 35 years than after it. BTMs were higher in women with low BMI ( beta CTX and OC), low alcohol consumption (PINP), current smoking habit (bone ALP and NTX), and around time of ovulation (NTX). Conclusions: We recommend that the age range 35 to 45 years should be used when establishing BTM reference ranges in women. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 36 条
[1]   The menopause and its treatment in perspective [J].
Al-Azzawi, F .
POSTGRADUATE MEDICAL JOURNAL, 2001, 77 (907) :292-304
[2]  
ALTMAN, 1991, PRACTICAL STAT MED R, P419
[3]   The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women [J].
Bjarnason, NH ;
Christiansen, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :590-596
[4]   Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women [J].
Burger, HG ;
Dudley, EC ;
Hopper, JL ;
Groome, N ;
Guthrie, JR ;
Green, A ;
Dennerstein, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :4025-4030
[5]   Changes in bone resorption during the menstrual cycle [J].
Chiu, KM ;
Ju, J ;
Mayes, D ;
Bacchetti, P ;
Weitz, S ;
Arnaud, CD .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (04) :609-615
[6]  
DICARLO C, 2007, J N AM MENOPAUSE SOC, V14, P1
[7]   Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate [J].
Eastell, R ;
Barton, I ;
Hannon, RA ;
Chines, A ;
Garnero, P ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (06) :1051-1056
[8]   Bone turnover markers and bone density across the menopausal transition [J].
Ebeling, PR ;
Atley, LM ;
Guthrie, JR ;
Burger, HG ;
Dennerstein, L ;
Hopper, JL ;
Wark, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3366-3371
[9]  
EVANS C, 1993, EFFECTS LOW HIGH SOD
[10]  
GAMERO P, 1994, J CLIN ENDOCR METAB, V79, P1693